This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (20)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Prognosis/ Outcomes  • Neoplasms  • Alert me on articles by topic

Julie B. Lowe, MD; Eva Hurst, MD; Jeffrey F. Moley, MD; Lynn A. Cornelius, MD

Arch Dermatol. 2003;139:617-621.

Objective  To define the percentage of positive sentinel lymph node biopsies and identify risk factors for the presence of lymph node disease in patients with melanomas less than or equal to 1 mm in depth.

Design  Retrospective chart review.

Setting  Washington University School of Medicine and Barnes-Jewish Hospital, St Louis, Mo, a melanoma referral center with outpatient surgical care.

Patients  Forty-six patients with melanomas less than or equal to 1 mm in depth undergoing sentinel lymph node biopsy at our institution between 1996 and 2002.

Results  The procedure was well tolerated and there were no reported complications. Of the 46 patients, 3 (7%) (95% exact confidence interval, 1.3%-17.8%) were found to have positive sentinel lymph nodes or micrometastatic disease. The finding of a positive sentinel lymph node was associated with a Clark level of III or more (P.07).

Conclusions  Conclusions from this study are limited by the small sample size. The results of our study suggest that sentinel lymph node biopsy of patients with melanomas less than or equal to 1 mm in depth may be indicated when the Clark level is III or more.

From the Divisions of Dermatology (Drs Lowe, Hurst, and Cornelius) and Surgical Oncology (Dr Moley), Washington University School of Medicine, St Louis, Mo. The authors have no relevant financial interest in this article.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Tumor-Infiltrating Lymphocytes Predict Sentinel Lymph Node Positivity in Patients With Cutaneous Melanoma
Taylor et al.
JCO 2007;25:869-875.
ABSTRACT | FULL TEXT  

The Prognostic Importance of Sentinel Lymph Node Biopsy in Thin Melanoma
Ranieri et al.
Ann. Surg. Oncol. 2006;13:927-932.
ABSTRACT | FULL TEXT  

Early-stage melanoma: staging criteria and prognostic modeling.
Ross
Clin. Cancer Res. 2006;12:2312s-2319s.
ABSTRACT | FULL TEXT  

Results of Sentinel Lymph Node Biopsy in Patients With Thin Melanoma
Wong et al.
Ann. Surg. Oncol. 2006;13:302-309.
ABSTRACT | FULL TEXT  

American Joint Committee on Cancer Clinical Stage as a Selection Criterion for Sentinel Lymph Node Biopsy in Thin Melanoma
Vaquerano et al.
Ann. Surg. Oncol. 2006;13:198-204.
ABSTRACT | FULL TEXT  

Sentinel Lymph Node Biopsy for Cutaneous Melanoma of the Head and Neck
MacNeill et al.
Ann. Surg. Oncol. 2005;12:726-732.
ABSTRACT | FULL TEXT  

Detection of Lymphatic Invasion in Primary Melanoma With Monoclonal Antibody D2-40: A New Selective Immunohistochemical Marker of Lymphatic Endothelium
Niakosari et al.
Arch Dermatol 2005;141:440-444.
ABSTRACT | FULL TEXT  

Indications for Lymphatic Mapping and Sentinel Lymphadenectomy in Patients with Thin Melanoma (Breslow Thickness <=1.0 mm)
Stitzenberg et al.
Ann. Surg. Oncol. 2004;11:900-906.
ABSTRACT | FULL TEXT  

Sentinel Lymph Node Biopsy: The Issue of Probability and Statistics
Bahmer
Arch Dermatol 2004;140:237-237.
FULL TEXT  

Sentinel Lymph Node Biopsy in Patients With Thin Melanoma
Kanzler
Arch Dermatol 2004;140:237-238.
FULL TEXT